Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU
Diabetes or With New Hyperglycemia
About this trial
This is an interventional treatment trial for Diabetes or With New Hyperglycemia focused on measuring ICU, hyperglycemia, glucommander
Eligibility Criteria
Inclusion Criteria:
- Males or females between the ages of 18 and 70 years admitted to a medical ICU
A known history of diabetes mellitus or with new hyperglycemia untreated or treated by diet, insulin therapy or with any combination of antidiabetic agents (sulfonylureas, metformin, thiazolidinediones).
- Blood glucose greater than 120 mg/dl on ≥ 2 occasions for known, treated diabetics or greater than 140 mg/dl on ≥ 2 occasions for those with new hyperglycemia.
- Subjects must have an admission blood glucose < 400 mg/dL, without laboratory evidence of diabetic ketoacidosis (serum bicarbonate < 18 milliequivalents/L or positive serum or urinary ketones).
Exclusion Criteria:
- Subjects with acute hyperglycemic crises such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state [38].
- Patients with known HIV, severely impaired renal function (serum creatinine ≥3.0 mg/dl).
- Patients with mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
- Female subjects who are pregnant or breast feeding at time of enrollment into the study.
Sites / Locations
- Grady Memorial Hospital
- Piedmont Hopsital
- University of Tennessee Health Science Center, Memphis
- University of Washington, Seattle
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Computer assisted IV insulin infusion
Standard insulin infusion algorithm
Subjects in this group will receive continuous intravenous (IV) Insulin Infusion using glucommander computer guided system. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
Subjects in this group will receive Insulin using Standard insulin infusion algorithm. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)